Pioglitazone is an insulin sensitizer that acts on the peroxisome proliferator-activated receptor γ (PPARγ) to reduce steatosis by increasing lipid oxidation, thereby preventing NASH (23). This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.